Advertisement

Zymogen Protein C to Prevent Clotting without Bleeding during Invasive Medical Procedures

  • Duane F. BruleyEmail author
  • Sanjay B. Jagannath
  • Micheal B. Streiff
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 701)

Abstract

Thrombophilic disorders that predispose patients to develop blood clots can be life-threatening and result in a large economic burden on healthcare expenditures. Venous Thromboembolism(VTE) (deep vein thrombosis and pulmonary embolism) are the third leading cause of death in the United States. ProteinCdeficiency is a common thrombophilic condition that affects an estimated 1 in 400 Americans. Zymogen Protein C (ZPC) is the precursor to Activated Protein C (APC), a pivotal endogenous anticoagulant in human blood. Patients with protein C deficiency who have roughly half the normal level of proteinC are estimated to be at 10-fold increased risk of VTE. We describe the use of protein C concentrate (Ceprotin®, Baxter, Deerfield, IL) in a patient with protein C deficiency and with a previous pulmonary embolism who developed a life-threatening gastrointestinal bleed after polypectomy. The patient is a 75-year-old male at very high risk for deep vein thrombosis and possible lung emboli. He has heterozygous Protein C deficiency (50%) and heterozygosity for the prothrombin gene G20210A mutation. During a routine colonoscopy, a large 3 cm cecal polyp was identified and resected. Eight days post-procedure while performing abdominal exercise he developed a life-threatening GI bleed originating from the polypectomy site as his warfarin was becoming therapeutic on a Low Molecular Weight Heparin (LMWH) periprocedural bridge. The patient’s warfarin was reversed with vitamin K, and LMWH and warfarin were discontinued. To prevent thrombosis, he was started on ZPC until anticoagulation could be safely restarted. During endoscopy, the bleeding site was treated with an injection of 1:10,000 dilution of epinephrine, followed by cauterization and placement of endoclips (4 metal staples). Three days after endoscopic repair LMWH was restarted with warfarin. Sixteen months post-bleed, the patient remains on life-long warfarin without further episodes of bleeding or thrombosis. Zymogen Protein C concentrate (Ceprotin®, Baxter Deerfield, IL) should be strongly considered for peri-procedural management of any patient with protein C deficiency and previous thromboembolism.

Keywords

International Normalize Ratio Invasive Medical Procedure Thrombophilic Disorder Large Economic Burden Prothrombin Gene G20210A Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bertina, R.M. (1988) Protein C and Related Proteins. Churchill Livingstone, New YorkGoogle Scholar
  2. 2.
    Bicher, H. I., Bruley, D. F., and Knisely, M. H (1973) Anti-adhesive drugs and tissue oxygenation, Advances in Experimental Medicine and Biology. Plenum Press, 37B:657-667.Google Scholar
  3. 3.
    Bourgain,R.H. (1978) The Effect of indomethacin and ASA on in-vivo induced white platlet thrombus formation, Thromb. Res., 12: 1079-1086.PubMedCrossRefGoogle Scholar
  4. 4.
    Bruley, D.F. (1998) Protein C-the ultimate anticoagulant/antithrombotic?, : anticoagulant, antithrombotic, and thrombolytic thearapeutics II, edited by C.A.Thibeault and L.M. Savage,IBC Library Series-Boston: 129-161.Google Scholar
  5. 5.
    Bruley, D. F. (2009) Zymogen protein c concentrate for safer heterozygote surgery, i am a guinea pig!”, Advances In Experimental Medicine and Biology, Oxygen Transport To Tissue XXX, Springer, Vol.645, : 115-121.Google Scholar
  6. 6.
    Bruley, D.F., Drohan, W.N. (1990) Advances in applied biotechnology series, protein c and related anticoagulants. 11, Gulf Publications, Houston, TX.Google Scholar
  7. 7.
    Bruley, D.F., Mears, S.C.and Streiff, M.B. (2010) Safer surgery using zymogen protein c concentrate, advances in experimental medicine and biology, oxygen transport to tissue XXXI, Springer, Vol. 662,:439-445.Google Scholar
  8. 8.
    Clouse, L.H., Comp, P.C. (1986) The regulation of hemostasis: the protein c system. N. Engl. J. Med 314:1298-1304.PubMedCrossRefGoogle Scholar
  9. 9.
    Comp, P. Esmon, C. (1981) Generation of fibrinolytic activity by infusion of activated protein c into dogs. J. Clin. Invest. 68:1221-1228.PubMedCrossRefGoogle Scholar
  10. 10.
    Dave,A.,Bruley,D.F.,Kang,K.A. (1999) Preliminary studies in the separation of human protein c from transgenic milk using immobilized metal affinity chromatography, oxygen transport to tissue XXI, Advances in Experimental Medicine and Biology, Kluwer Academic/Plenum Publishers,NY, Vol.471,639-647.Google Scholar
  11. 11.
    Esmon, C. T. (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743.PubMedGoogle Scholar
  12. 12.
    Esmon C.T. (1990) Regulation of coagulation the nature of the problem, protein c and related anticoagulants, Advances In Biotechnology Series,Vol II. Editors,Duane F. Bruley andWilliam N. Drohan, Gulf Publishing Company, Houston.Google Scholar
  13. 13.
    Gruber, A., Griffin, J.H. Harker, L.A., Hanson, S.R. (1989) Inhibition of platelet-dependent thrombosis formation by human activated protein c in a primate model, Blood. 73:639-642.PubMedGoogle Scholar
  14. 14.
    Hyde E.,Wetmore R.,GurewichV. (1974) Isolation and characterization of an in-vivo thrombininduced anticoagulant activity, Scandinavian Journal of Haematology 13: 121-128.Google Scholar
  15. 15.
    Kisiel W. (1979) Human plasma protein c., isolation, characterization and mechanism of activation by a-thrombin, Journal of Clinical Investigation 64: 761-769.PubMedCrossRefGoogle Scholar
  16. 16.
    Mammen E.F., et.al (1960) Handbook of proteolytic enzymes, Edited by Alan J Barrett, Neil D Rawlings and Fred J. Woessneer, CLAN SA-SI, 56 Protein C, pp 174, Academic Press.Google Scholar
  17. 17.
    Marciniak, E. (1972) Inhibitor of human blood coagulation elicited by thrombin, Journal of Laboratory and Clinical Medicine 79: 924-934.PubMedGoogle Scholar
  18. 18.
    Marlar, R.A. (1981) Records, The Milwaukee Blood Center, Milwaukee, WI, USA.Google Scholar
  19. 19.
    Marlar,R.A.,Montgomery, R. R.,Broakman, A.W. (1989) Diagnosis and treatment of homozygous protein c deficiency. Report of the working party on homozygous protein C deficiency of the subcommittee on protein C and protein S, International Committee on Thrombosis and Haemostasis, J. Paediatrics. 114:528-534.CrossRefGoogle Scholar
  20. 20.
    Porath, J. (1992) Immobilized metal ion affinity chromatography, Prot. Express. Purif. 3:263-281.CrossRefGoogle Scholar
  21. 21.
    Porath, J., Carlsson, J., Olsson, I., Belfrage, G. (1975) Metal chelate affinity chromatography, a new approach to protein fractionation, Nature. 258:598-599.PubMedCrossRefGoogle Scholar
  22. 22.
    Rapaport, S. I. (1989) Blood 73,359.PubMedGoogle Scholar
  23. 23.
    Rosenberg, R. and Marcum, J. A. (1985) ASAIO J. 8, 215.Google Scholar
  24. 24.
    Seegers W. H., Novea E., Henry R.L., Hassouna H. I. (1976) Relationship of ‘new’ vitamin k-dependent protein c and ‘old’ autoprothrombin II-a, Thrombosis Research 8:543-552.PubMedCrossRefGoogle Scholar
  25. 25.
    Stenflo J.(1976) A new vitamin K-dependent protein, Journal of Biological Chemistry 25: 355-363.Google Scholar
  26. 26.
    Thakkar,S.C., Streiff,M.B., Bruley,D.F., Mears,S.C., Case report: perioperative use of protein c concentrate for protein c deficiency in tha, Clinical Orthopaedics and Related Research, Springer, N.Y. (accepted for publication).Google Scholar
  27. 27.
    Weiss, P., Soff,G.A., Halkin,H., Seligsohn,U. (1987) Decline of protein c and s and factors II, VII, IX and X during the initiation of warfarin therapy, Thrombosis Research 45, 783-790.Google Scholar
  28. 28.
    Wu, H., Bruley, D. F. (1999) Homologous blood protein separation using immobilized metal affinity chromatography – protein c separation from prothrombin with application to the separation of factor IX and prothrombin, Biotechnol. Prog. 15:928-931.PubMedCrossRefGoogle Scholar
  29. 29.
    Wu, H., Bruley, D. F. (2002) Chelator, metal ion and buffer studies for protein c separation, Comparative Biochemistry and Physiology, Part A. 132:213-220.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Duane F. Bruley
    • 1
    Email author
  • Sanjay B. Jagannath
    • 2
  • Micheal B. Streiff
    • 3
  1. 1.Synthesizer, Inc.Ellicott CityUSA
  2. 2.Pancreatitis Center, Division of GastroenterologyJohns Hopkins HospitalBaltimoreUSA
  3. 3.Anticoagulation Management Service,Division of Hematology, Department of MedicineJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations